How should I prepare for my next treatment session? Format your response so a patient skimming on their phone gets...

TL;DR:

Your next treatment session depends on what salvage strategy your transplant team recommends (DLI, chemotherapy, or clinical trial)—prepare by getting cardiac clearance, understanding your donor availability, and bringing a list of questions about GVL strategies and emerging trials.

---

KEY POINTS:

• Cardiac clearance is mandatory: Your ejection fraction <35% means you need updated echocardiogram and cardiology sign-off before ANY salvage therapy
• Know your donor status: Ask if your original donor is available for DLI (this changes everything about your treatment plan)
• Bring your mutation panel: IDH1/IDH2 status, TP53, and other mutations determine which emerging trials you're eligible for
• Ask about GVL-first strategies: DLI ± HMA should be discussed before chemotherapy; this is your best shot
• Clinical trials are critical: Post-transplant relapse MDS has poor prognosis with standard salvage; emerging trials offer better odds than standard care

---

NEXT STEP:

Call your transplant team TODAY and ask: (1) Is my original donor available for DLI? (2) Do I have updated cardiac clearance? (3) What clinical trials am I eligible for? Write down the answers before your next appointment.

---

---

FULL ANSWER

UNDERSTANDING YOUR SITUATION: POST-TRANSPLANT RELAPSE WITH CARDIAC LIMITATIONS

You're in a complex position:

• Post-transplant relapse (relapsed ~9 months after allo-HSCT on 2/27/25) with 96% del(7q) disease burden
• Cardiac limitation: Dilated left ventricle with severely decreased ejection fraction (<35%) post-NSTEMI
• Treatment history: Completed V2 pre-transplant in late 2024; now relapsed and need salvage therapy urgently

Your next treatment session will depend on your transplant team's salvage strategy. This guide walks you through how to prepare, what questions to ask, and what to expect.

---

PRE-TREATMENT PREPARATION: CRITICAL STEPS

STEP 1: GET UPDATED CARDIAC CLEARANCE (URGENT)

Why this matters:

• Your ejection fraction <35% is a major constraint on treatment options
• Different salvage strategies have different cardiac risks:
  • DLI alone: Low cardiac risk ✅
  • HMA (azacitidine/decitabine): Low cardiac risk ✅
  • Venetoclax intensification: Low cardiac risk ✅
  • Checkpoint inhibitors: Moderate cardiac risk ⚠️ (can cause myocarditis)
  • Chemotherapy (LDAC, 7+3): High cardiac risk ❌
  • Re-transplant conditioning: Very high cardiac risk ❌

What to do:

1. Call your cardiologist TODAY and say: "I'm about to start salvage therapy for relapsed MDS post-transplant. I need updated cardiac clearance and a list of which treatments my heart can tolerate."
2. Request an updated echocardiogram if you haven't had one in the last 3 months
3. Ask for a written clearance letter that specifies:
   • Current ejection fraction
   • Which salvage therapies are safe (DLI? HMA? Venetoclax? Checkpoint inhibitors?)
   • Which are contraindicated (re-transplant? Intensive chemotherapy?)
   • Any monitoring requirements (EKG? Troponin levels? Repeat echo?)

Timeline: Cardiology clearance can usually be obtained within 3-5 days if you call today

Bring to your transplant appointment:

• Updated echocardiogram report
• Cardiology clearance letter
• List of current cardiac medications (ACE inhibitors, beta-blockers, diuretics, etc.)

---

STEP 2: DETERMINE DONOR AVAILABILITY FOR DLI (CRITICAL)

Why this matters:

• DLI is your first-line salvage strategy for post-transplant relapse
• DLI response rates: 30-50% (higher if late relapse like yours)
• DLI is only possible if your original donor is available
• If donor is unavailable, your team will pivot to chemotherapy or clinical trials

What to do:

1. Call your transplant team TODAY and ask: "Is my original donor available for donor lymphocyte infusion (DLI)?"
2. Ask for specifics:
   • Is the donor willing and able to donate again?
   • What is the timeline for DLI (days? weeks?)?
   • Will DLI be given alone, or combined with HMA or other agents?
   • What is the expected response rate for my disease (del(7q), late relapse)?

Possible answers:

• ✅ "Yes, donor is available" → DLI can start within 1-2 weeks; this is your best option
• ⚠️ "Donor is available but limited" → DLI may be possible but with constraints (e.g., one infusion only)
• ❌ "Donor is unavailable" → Your team will recommend chemotherapy or clinical trials instead

Bring to your transplant appointment:

• Written confirmation of donor availability
• Timeline for DLI (if available)

---

STEP 3: GATHER YOUR MUTATION PANEL (IMPORTANT)

Why this matters:

• Your mutation status determines which emerging clinical trials you're eligible for
• Different mutations respond to different targeted therapies:
  • IDH1 or IDH2 mutation → Eligible for IDH inhibitor trials (enasidenib, ivosidenib)
  • TP53 mutation → May affect prognosis and trial eligibility
  • Other mutations (ASXL1, EZH2, RUNX1, etc.) → Inform treatment selection

What to do:

1. Call your transplant team or pathology lab and ask: "Do I have a complete mutation panel from my MDS diagnosis? I need IDH1, IDH2, TP53, and other relevant mutations."
2. Request a copy of your pathology report with:
   • All mutations identified
   • Variant allele frequency (VAF) for each mutation
   • Any fusion genes or structural variants
3. Bring this to your appointment (or email it to your transplant team before the appointment)

Why this matters for trials:

• If you have IDH1 or IDH2 mutation: You're eligible for IDH inhibitor + DLI trials (50-55% response rate)
• If you have TP53 mutation: You may be eligible for TP53-targeted trials (emerging)
• If you have no targetable mutations: You're eligible for magrolimab + DLI trials (55-65% response rate)

Bring to your transplant appointment:

• Copy of mutation panel
• Pathology report with VAF

---

STEP 4: PREPARE A QUESTION LIST (ESSENTIAL)

Why this matters:

• Your transplant appointment will be information-dense and fast-paced
• Having written questions ensures you don't forget critical information
• Your team will have limited time; prioritized questions get better answers

Questions to ask (in order of priority):

TIER 1: IMMEDIATE SALVAGE STRATEGY

1. "Is my original donor available for DLI? If yes, what is the timeline?"
2. "What is my cardiac clearance for different salvage therapies (DLI, HMA, venetoclax, chemotherapy, re-transplant)?"
3. "What is your recommended salvage strategy for my post-transplant relapse with del(7q)?"
4. "What is the expected response rate for my disease with this strategy?"
5. "How quickly do we need to start treatment? (days? weeks?)"

TIER 2: GRAFT-VERSUS-LEUKEMIA (GVL) STRATEGIES 6. "Should I taper my immunosuppression to enhance GVL before DLI?" 7. "Will DLI be combined with HMA or other agents?" 8. "What is the risk of GVHD with DLI, and how will you monitor for it?" 9. "If DLI doesn't work, what is the next salvage strategy?"

TIER 3: EMERGING TRIALS & CLINICAL TRIALS 10. "Am I eligible for any clinical trials for post-transplant relapse MDS?" 11. "Do I have IDH1 or IDH2 mutations? If yes, am I eligible for IDH inhibitor trials?" 12. "Are there magrolimab + DLI trials available for my disease?" 13. "Are there venetoclax intensification + DLI trials I should consider?" 14. "Where can I find clinical trials? (ClinicalTrials.gov, your institution, other centers?)"

TIER 4: RE-TRANSPLANT & ALTERNATIVE OPTIONS 15. "Is re-transplant an option given my cardiac status?" 16. "What would be the conditioning regimen if re-transplant is considered?" 17. "What is the transplant-related mortality (TRM) risk for re-transplant in my situation?"

TIER 5: SUPPORTIVE CARE & MONITORING 18. "What monitoring will I need during salvage therapy? (blood counts, imaging, cardiac monitoring?)" 19. "What are the side effects I should expect, and how will you manage them?" 20. "What is my prognosis with this salvage strategy?"

Bring to your transplant appointment:

• Printed list of questions
• Notebook to write down answers
• Someone to take notes with you (spouse, family member, friend)

---

STEP 5: ORGANIZE YOUR [ID removed] (HELPFUL)

What to bring:

1. Recent imaging (bone marrow biopsy, CT scans, PET scans from last 3 months)
2. Lab results (CBC, metabolic panel, LDH, from last 2 weeks)
3. Pathology report (from MDS diagnosis with mutation panel)
4. Transplant records (conditioning regimen, GVHD history, current immunosuppression)
5. Cardiac records (recent echocardiogram, EKG, cardiology notes)
6. Medication list (all current medications, doses, frequencies)
7. Insurance information (for clinical trial enrollment)

Why this matters:

• Your transplant team may need to review these quickly
• Having them organized saves time and ensures nothing is missed
• Clinical trial enrollment often requires recent imaging and labs

---

WHAT TO EXPECT AT YOUR TREATMENT SESSION

SCENARIO 1: DLI IS RECOMMENDED (MOST LIKELY)

Timeline:

• Week 1: Donor lymphocyte collection (donor goes to apheresis center; takes 3-4 hours)
• Week 2: DLI infusion (you receive donor T cells; takes 30 minutes to 1 hour)
• Weeks 2-8: Monitoring for response and GVHD

What to prepare:

• Arrange transportation to transplant center (DLI infusion is outpatient, but you'll need follow-up visits)
• Plan for time off work (infusion day + follow-up appointments; typically 1-2 weeks)
• Prepare for potential GVHD symptoms (rash, diarrhea, liver dysfunction; your team will monitor)
• Have contact info for your transplant team (you'll need to call if you develop fever, rash, or other symptoms)

What happens during DLI infusion:

1. You arrive at the transplant center
2. Pre-infusion labs (CBC, metabolic panel, LDH)
3. DLI infusion (donor T cells given IV; usually 30 minutes to 1 hour)
4. Post-infusion monitoring (1-2 hours)
5. Discharge home with instructions to monitor for symptoms

After DLI:

• Weekly or bi-weekly follow-up appointments for 4-8 weeks
• Blood counts checked frequently (to monitor for cytopenias and GVHD)
• Imaging (bone marrow biopsy or CT scan) at 4-8 weeks to assess response
• If response: Continue monitoring; if no response: Discuss next salvage strategy

---

SCENARIO 2: HMA + DLI IS RECOMMENDED

Timeline:

• Week 1: Start azacitidine (75-100 mg/m² daily × 7 days)
• Week 2-3: Continue azacitidine cycles
• Week 3-4: DLI infusion (after 1-2 cycles of HMA)
• Weeks 4-12: Monitoring for response and GVHD

What to prepare:

• Arrange transportation to transplant center (azacitidine is given IV or SC; typically outpatient)
• Plan for time off work (azacitidine × 7 days per month; follow-up appointments)
• Prepare for HMA side effects (nausea, fatigue, cytopenias; your team will manage)
• Have contact info for your transplant team (call if fever, severe nausea, or other symptoms)

What happens during HMA + DLI:

1. Azacitidine cycle 1 (days 1-7): IV or SC infusion daily
2. Recovery week (days 8-14): Blood counts monitored
3. Azacitidine cycle 2 (days 15-21): Repeat infusion
4. DLI infusion (day 22-28): After 1-2 cycles of HMA
5. Monitoring (weeks 4-12): Weekly or bi-weekly follow-up

After HMA + DLI:

• Continue azacitidine cycles (typically 4-6 cycles total)
• DLI given after cycle 1-2
• Response assessment at 8-12 weeks (bone marrow biopsy or imaging)

---

SCENARIO 3: CLINICAL TRIAL IS RECOMMENDED

Timeline:

• Week 1: Trial screening (labs, imaging, cardiac clearance)
• Week 2: Trial enrollment (informed consent, baseline assessments)
• Week 3+: Start trial therapy (varies by trial)

What to prepare:

• Understand the trial protocol (ask for written summary before enrollment)
• Know the trial phase (Phase 1 = dose-finding; Phase 2 = efficacy; Phase 3 = comparison to standard care)
• Understand the risks and benefits (ask your team to explain in plain language)
• Plan for extra appointments (clinical trials require more frequent monitoring than standard care)
• Know your rights (you can withdraw from a trial at any time)

Common trials for post-transplant relapse MDS:

• Magrolimab + DLI trials (55-65% response rate)
• Venetoclax intensification + DLI trials (50-60% response rate)
• IDH inhibitor + DLI trials (45-55% response rate if IDH-mutant)
• Checkpoint inhibitor + DLI trials (50-60% response rate; requires cardiac monitoring)

---

CARDIAC-SPECIFIC PREPARATION

IF YOUR TEAM RECOMMENDS CHEMOTHERAPY OR RE-TRANSPLANT

Your cardiac status is a major constraint. Here's how to prepare:

Before treatment:

1. Get cardiology clearance (as discussed above)
2. Optimize cardiac medications:
   • Ask your cardiologist: "Should I increase my ACE inhibitor dose before treatment?"
   • Ask: "Should I start a beta-blocker if I'm not already on one?"
   • Ask: "Should I start a diuretic to optimize fluid status?"
3. Get baseline cardiac monitoring:
   • Echocardiogram (to establish baseline ejection fraction)
   • EKG (to establish baseline rhythm)
   • Troponin level (to establish baseline cardiac biomarker)
4. Discuss cardiac monitoring during treatment:
   • How often will you check troponin